Result of testosterone (name of drug)in liver disease
Not Applicable
- Conditions
- Health Condition 1: K740- Hepatic fibrosis
- Registration Number
- CTRI/2019/08/021000
- Lead Sponsor
- Institute of Liver and Biliary Sciences
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Open to Recruitment
- Sex
- Not specified
- Target Recruitment
- 0
Inclusion Criteria
1) Men with cirrhosis of any etiology
2) Sarcopenia
3) CTP 6-12
Exclusion Criteria
1) Hepatocellular carcinoma
2) Other known malignancy,
3) CTP > 12
4) Acute liver injury
5) Prostate disease,
6) Known hypersensitivity to testosterone therapy,
Polycythaemia (haematocrit >55%),
7) Uncontrolled hypertension ( >160/90 mmHg despite treatment),
8) Uncontrolled obstructive sleep apnoea,
9) Severe renal dysfunction (estimated glomerular filtration rate <30ml/min)
10) Uncontrolled epilepsy, migraine, or significant cardiac insufficiency (New York Heart Association class III or IV or LVEF < 45-50%.
11) CKD (Chronic Kidney Disease) - eGFR (Glomerular Filtration Rate) <60%
12) Platelet count below 30,000 or taking warfarin
13) Failure to give consent.
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method